Arimidex 120511-73-1

Arimidex 120511-73-1

Name: Anastrozole powder
CAS: 120511-73-1
Molecular Formula: C17H19N5
Molecular Weight: 293.37
Melt Point: 81-82°C
Color: White crystalline powder
Arimidex is White crystalline powder

Product Introduction
What is Arimidex(120511-73-1) powder?

 

Arimidex(120511-73-1), also known as Anastrozole, is a medicine that contains the active substance anastrozole. It is used to treat breast cancer in women who have already gone through menopause. Arimidex belongs to a group of medicines called 'aromatase inhibitors' which reduce the amount of the hormone estrogen made in the body by blocking the action of an enzyme in the body called 'aromatase'. Decreasing the production of estrogen is a way of suppressing the growth of breast cancer because the growth of breast tissue is stimulated by estrogen.

 

Arimidex quick details

 

Name: Anastrozole powder

CAS: 120511-73-1

Molecular Formula: C17H19N5

Molecular Weight: 293.37

Melt Point: 81-82°C

Color: White crystalline powder

Arimidex is White crystalline powder

product-675-506

 

 

What does Arimidex do to the body?

 

Estrogen is a hormone that plays a key role in the growth and development of breast cancer. It is produced in the body by an enzyme called aromatase, which converts androgens (male hormones) into estrogen. By blocking the activity of aromatase, Arimidex reduces the amount of estrogen in the body, which can slow or stop the growth of breast cancer cells.

 

In addition to its use in breast cancer treatment, Arimidex has also been used off-label to treat infertility in women with ovulatory disorders. In these cases, Arimidex can help to stimulate ovulation by reducing the levels of estrogen in the body, which can interfere with the normal hormonal balance required for ovulation.

 

Arimidex Dosage

 

The dose of Arimidex is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Arimidex should be continued until tumor progression. Arimidex can be taken with or without food.

For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, ARIMIDEX was administered for five years.

No dosage adjustment is necessary for patients with renal impairment or for elderly patients

 

Hot Tags: Arimidex 120511-73-1, China Arimidex 120511-73-1 manufacturers, suppliers, factory, GTX-007, Flibanserin, MK-2866, Arimidex, Minoxidil, Raloxifene Powder

Send Inquiry

whatsapp

Phone

E-mail

Inquiry

Bag